Luca Santarelli
CEO & Chair of the Board of DirectorsDr. Luca Santarelli M.D., is Founder and CEO of Windward Bio AG and Windward Bio Group AG and also serves as its Chairman from January 2025. Dr. Santarelli is Chair of Board of Directors of Alentis Therapeutics AG since June 2023. Dr. Santarelli is the Founder and Chief Executive Officer of VectivBio Holding AG and has been its Director since May 2019. Dr. Santarelli served as a Member of Scientific Advisory Board at Curasen Therapeutics Inc. until 2025. Dr. Santarelli served as Chairman of Dementia Discovery Fund at SV Health Investors, LLC till February 2025. He has been Chief Executive Officer of TherAchon SAS since January 5, 2017. From January 2016 to June 2019 Dr. Santarelli was the Co-founder & Chief Executive Officer and a member of the board of directors at Therachon Holding AG. He co-founded or helped create a number of life science companies, including Synosia Therapeutics and Flexion Therapeutics. Dr. Santarelli served as a Venture Partner at Versant Venture Management, LLC. At Versant Ventures, he played operating or board roles in select portfolio companies and worked to identify new biotech investment opportunities. He has extensive experience in academic, industrial research and development and business experience. Dr. Santarelli has been Independent Non-Executive Director at Alentis Therapeutics AG since November 2021. Dr. Santarelli was a Senior Vice President and Global Head of Neuroscience, Ophthalmology and Rare Diseases at Roche. In this capacity, he built a multi-disciplinary team and led efforts spanning from drug discovery to early development. Dr. Santarelli has operating experience from his progressive leadership responsibilities at Roche. He also provided strategic and operational leadership for many of the Roche external biotech collaborations and helped instill a more entrepreneurial culture in the broader R&D organization. At Roche, he advanced many new molecular entities (NMEs) to the clinic, various NMEs to registration studies including gantenerumab in Alzheimer's disease and spearheaded the development of several drug candidates that have now reached approval, including ocrelizumab in multiple sclerosis and risdiplan in spinal muscular atrophy. He has been a Director of TherAchon SAS since January 5, 2017 He is a Discovery Scientist and Clinician. Dr. Santarelli is an entrepreneurial pharmaceutical executive with a background in academic research and many years of experience in R&D and as a biotech CEO. He has led drug programs in the areas of neuroscience, rare diseases, ophthalmology, metabolic and G.I., spanning the value chain from discovery research to commercialization. Dr. Santarelli also provided strategic and operational leadership for many of the Roche external biotech collaborations and helped instill a more entrepreneurial culture in the broader R&D organization. During this period, he catalyzed the creation of Synosia. Previously, he was a Research Scientist at Columbia University and a co-founder of BrainCells Inc. Dr. Santarelli received his M.D. and Psychiatry Residency at the University of Turin and Post-Doctorate fellowship at Columbia University where he also co-founded a venture backed startup while on faculty.
Positions
- Company NameWindward Bio Group AGStock CodeWWBPositionCEO & Chair of the Board of DirectorsColleagues
- CDClaudia D'AugustaChief Financial Officer
- KAKevin Andrew HarrisChief Operating Officer
- NKNoel KurdiSenior Vice President of Investor Relations & Communications
- SAScott ApplebaumChief Legal & Corporate Development Officer
- SSSandip S. KapadiaLead Independent Director
- DBDavid BonitaIndependent Director
- OSOtello StampacchiaIndependent Director
- IRIqbal Rasool MuftiIndependent Director
